{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T04:43:56Z","timestamp":1790484236369,"version":"4.1.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,6,1]],"date-time":"2017-06-01T00:00:00Z","timestamp":1496275200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"R.U.O.T.A."}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology in Vitro"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1016\/j.tiv.2017.02.008","type":"journal-article","created":{"date-parts":[[2017,2,21]],"date-time":"2017-02-21T02:02:02Z","timestamp":1487642522000},"page":"49-55","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Reduced cell viability and apoptosis induction in human thyroid carcinoma and mesothelioma cells exposed to cidofovir"],"prefix":"10.1016","volume":"41","author":[{"given":"Simona","family":"Catalani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Palma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serafina","family":"Battistelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Nuvoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Galati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serena","family":"Benedetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tiv.2017.02.008_bb0005","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrc2657","article-title":"p21 in cancer: intricate networks and multiple activities","volume":"9","author":"Abbas","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.tiv.2017.02.008_bb0010","first-page":"523","article-title":"Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines","volume":"10","author":"Andrei","year":"1998","journal-title":"Oncol. Res."},{"key":"10.1016\/j.tiv.2017.02.008_bb0015","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3727\/096504001108747855","article-title":"Induction of apoptosis by cidofovir in human papillomavirus (HPV)-positive cells","volume":"12","author":"Andrei","year":"2000","journal-title":"Oncol. Res."},{"key":"10.1016\/j.tiv.2017.02.008_bb0020","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.antiviral.2014.10.012","article-title":"Insights into the mechanism of action of cidofovir and other acyclic nucleoside phosphonates against polyoma- and papillomaviruses and non-viral induced neoplasia","volume":"114","author":"Andrei","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.tiv.2017.02.008_bb0025","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.tiv.2017.02.008_bb0030","first-page":"562","article-title":"Topical 1% cidofovir for the treatment of basal cell carcinoma","volume":"12","author":"Calista","year":"2002","journal-title":"Eur. J. Dermatol."},{"key":"10.1016\/j.tiv.2017.02.008_bb0035","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1136\/bjo.86.8.932","article-title":"Successful treatment of squamous cell carcinoma of the lower eyelid with intralesional cidofovir","volume":"86","author":"Calista","year":"2002","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.tiv.2017.02.008_bb0040","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/1756-9966-32-63","article-title":"Metabolism modifications and apoptosis induction after Cellfood\u2122 administration to leukemia cell lines","volume":"32","author":"Catalani","year":"2013","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.tiv.2017.02.008_bb0045","doi-asserted-by":"crossref","first-page":"7412","DOI":"10.1158\/0008-5472.CAN-04-2077","article-title":"Clusterin-mediated apoptosis is regulated by adenomatous polyposis coli and is p21 dependent but p53 independent","volume":"64","author":"Chen","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.tiv.2017.02.008_bb0050","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1038\/nrd1877","article-title":"Acyclic nucleoside phosphonates: a key class of antiviral drugs","volume":"4","author":"De Clercq","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.tiv.2017.02.008_bb0055","first-page":"18","article-title":"Cidofovir selectivity is based on the different response of normal and cancer cells to DNA damage","volume":"6","author":"De Schutter","year":"2013","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.tiv.2017.02.008_bb0060","doi-asserted-by":"crossref","first-page":"25549","DOI":"10.18632\/oncotarget.8224","article-title":"Phase I trial evaluating the antiviral agent Cidofovir in combination with chemoradiation in cervical cancer patients","volume":"7","author":"Deutsch","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.tiv.2017.02.008_bb0065","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.4161\/cc.5.24.3559","article-title":"Claspin: timing the cell cycle arrest when the genome is damaged","volume":"5","author":"Freire","year":"2006","journal-title":"Cell Cycle"},{"key":"10.1016\/j.tiv.2017.02.008_bb0070","doi-asserted-by":"crossref","first-page":"6473","DOI":"10.1158\/1078-0432.CCR-13-1121","article-title":"Cidofovir: a novel antitumor agent for glioblastoma","volume":"19","author":"Hadaczek","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.tiv.2017.02.008_bb0075","first-page":"2562","article-title":"Potent inhibition of hemangioma formation in rats by the acyclic nucleoside phosphonate analogue cidofovir","volume":"58","author":"Liekens","year":"1998","journal-title":"Cancer Res."},{"key":"10.1016\/j.tiv.2017.02.008_bb0080","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/1097-0215(200102)9999:9999<::AID-IJC1183>3.0.CO;2-K","article-title":"Potent inhibition of hemangiosarcoma development in mice by cidofovir","volume":"92","author":"Liekens","year":"2001","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.tiv.2017.02.008_bb0085","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.18632\/oncotarget.3079","article-title":"The broad-spectrum anti-DNA virus agent cidofovir inhibits lung metastasis of virus-independent, FGF2-driven tumors","volume":"6","author":"Liekens","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.tiv.2017.02.008_bb0090","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.10100","article-title":"Cidofovir is active against human papillomavirus positive and negative head and neck and cervical tumor cells by causing DNA damage as one of its working mechanisms","author":"Mertens","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.tiv.2017.02.008_bb0095","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1080\/08958370600835377","article-title":"The role of SV40 in malignant mesothelioma and other human malignancies","volume":"18","author":"Pershouse","year":"2006","journal-title":"Inhal. Toxicol."},{"key":"10.1016\/j.tiv.2017.02.008_bb0100","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/978-1-4615-4743-3_10","article-title":"Cidofovir. Review of current and potential clinical uses","volume":"458","author":"Safrin","year":"1999","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.tiv.2017.02.008_bb0105","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00204-014-1448-7","article-title":"The mystery of BCL2 family: Bcl-2 proteins and apoptosis: an update","volume":"89","author":"Siddiqui","year":"2015","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.tiv.2017.02.008_bb0110","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1002\/cncr.23904","article-title":"Expression of the embryonic lethal abnormal vision-like protein HuR in human mesothelioma: association with cyclooxygenase-2 and prognosis","volume":"113","author":"Stoppoloni","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.tiv.2017.02.008_bb0115","first-page":"9","article-title":"Synergistic effect of gefitinib and rofecoxib in mesothelioma cells","volume":"2","author":"Stoppoloni","year":"2010","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.tiv.2017.02.008_bb0120","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/S1470-2045(14)70456-5","article-title":"Activity, safety, and feasibility of cidofovir and imiquimod for treatment of vulval intraepithelial neoplasia (RT3VIN): a multicentre, open-label, randomised, phase 2 trial","volume":"15","author":"Tristram","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tiv.2017.02.008_bb0125","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/jmv.21165","article-title":"Treatment of locally recurrent Epstein-Barr virus-associated nasopharyngeal carcinoma using the anti-viral agent cidofovir","volume":"80","author":"Yoshizaki","year":"2008","journal-title":"J. Med. Virol."}],"container-title":["Toxicology in Vitro"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233317300309?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887233317300309?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,18]],"date-time":"2019-09-18T18:28:31Z","timestamp":1568831311000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887233317300309"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6]]},"references-count":25,"alternative-id":["S0887233317300309"],"URL":"https:\/\/doi.org\/10.1016\/j.tiv.2017.02.008","relation":{},"ISSN":["0887-2333"],"issn-type":[{"value":"0887-2333","type":"print"}],"subject":[],"published":{"date-parts":[[2017,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reduced cell viability and apoptosis induction in human thyroid carcinoma and mesothelioma cells exposed to cidofovir","name":"articletitle","label":"Article Title"},{"value":"Toxicology in Vitro","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tiv.2017.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}